Immediate-release Sandostatin
- To reduce growth hormone and IGF-I (somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses.
- For the symptomatic treatment of patients with metastatic carcinoid tumors where it suppresses or inhibits severe diarrhea and flushing episodes associated with the disease.
- For treatment of profuse watery diarrhea associated with vasoactive intestinal peptide (VIP) secreting tumors.
Sandostatin LAR
Sandostatin LAR is a somatostatin analogue indicated in patients in whom initial treatment with Sandostatin Injection has been shown to be effective and tolerated.
- Long-term maintenance therapy in acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option.
- Long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors
- Long-term treatment of the profuse watery diarrhea associated with VIP-secreting tumors.